Cardiology overview heart failure: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 9: | Line 9: | ||
===Metformin=== | ===Metformin=== | ||
*[[Metformin]] use in [[diabetics]] with [[CHF]] is associated with lower mortality | *[[Metformin]] use in [[diabetics]] with [[CHF]] is associated with lower mortality | ||
===Enoxaparin and Antiocagulation=== | |||
* While hospitalized, patients with CHF should receive [[DVT prophylaxis]] | |||
==Invasive Monitoring== | ==Invasive Monitoring== | ||
Revision as of 15:36, 31 October 2011
|
Cardiology Overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Pharmacotherapy
Lasix
- Higher lasix doses are associated with higher mortality, likely as a surrogate of disease severity rather than part of a causal pathway.
Metformin
Enoxaparin and Antiocagulation
- While hospitalized, patients with CHF should receive DVT prophylaxis
Invasive Monitoring
- Based upon the results of the ESCAPE trial, there is no benefit in clinical outcomes with the use of a pulmonary artery line in patients with decompensated CHF.
Obstructive Sleep Apnea in the Patient with CHF
- Central sleep apnea in the patient with CHF is due to the compensatory respiratory alkalosis that is present in the patient with CHF and tachypnea